Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

Two closely related Env antigens from the same patient elicited different spectra of neutralizing antibodies against heterologous HIV-1 isolates.

Vaine M, Duenas-Decamp M, Peters P, Liu Q, Arthos J, Wang S, Clapham P, Lu S.

J Virol. 2011 May;85(10):4927-36. doi: 10.1128/JVI.00081-11. Epub 2011 Mar 16.

2.

Env-2dCD4 S60C complexes act as super immunogens and elicit potent, broadly neutralizing antibodies against clinically relevant human immunodeficiency virus type 1 (HIV-1).

Killick MA, Grant ML, Cerutti NM, Capovilla A, Papathanasopoulos MA.

Vaccine. 2015 Nov 17;33(46):6298-306. doi: 10.1016/j.vaccine.2015.09.056. Epub 2015 Oct 1.

PMID:
26432912
3.

Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies.

Malherbe DC, Doria-Rose NA, Misher L, Beckett T, Puryear WB, Schuman JT, Kraft Z, O'Malley J, Mori M, Srivastava I, Barnett S, Stamatatos L, Haigwood NL.

J Virol. 2011 Jun;85(11):5262-74. doi: 10.1128/JVI.02419-10. Epub 2011 Mar 23.

4.

Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody.

Cheng C, Pancera M, Bossert A, Schmidt SD, Chen RE, Chen X, Druz A, Narpala S, Doria-Rose NA, McDermott AB, Kwong PD, Mascola JR.

J Virol. 2015 Dec 30;90(6):2740-55. doi: 10.1128/JVI.02380-15.

5.

HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.

Wang Y, O'Dell S, Turner HL, Chiang CI, Lei L, Guenaga J, Wilson R, Martinez-Murillo P, Doria-Rose N, Ward AB, Mascola JR, Wyatt RT, Karlsson Hedestam GB, Li Y.

J Virol. 2017 Oct 13;91(21). pii: e00910-17. doi: 10.1128/JVI.00910-17. Print 2017 Nov 1.

PMID:
28835491
6.

Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits.

Malherbe DC, Pissani F, Sather DN, Guo B, Pandey S, Sutton WF, Stuart AB, Robins H, Park B, Krebs SJ, Schuman JT, Kalams S, Hessell AJ, Haigwood NL.

J Virol. 2014 Nov;88(22):12949-67. doi: 10.1128/JVI.01812-14. Epub 2014 Sep 10.

7.

Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.

Ingale J, Tran K, Kong L, Dey B, McKee K, Schief W, Kwong PD, Mascola JR, Wyatt RT.

J Virol. 2014 Dec;88(24):14002-16. doi: 10.1128/JVI.02614-14. Epub 2014 Sep 24. Erratum in: J Virol. 2015 Jun;89(12):6526.

8.
9.

Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.

Townsley S, Mohamed Z, Guo W, McKenna J, Cleveland B, LaBranche C, Beaumont D, Shen X, Yates NL, Pinter A, Tomaras GD, Ferrari G, Montefiori DC, Hu SL.

J Virol. 2016 Sep 12;90(19):8644-60. doi: 10.1128/JVI.00853-16. Print 2016 Oct 1.

10.

DNA prime-protein boost using subtype consensus Env was effective in eliciting neutralizing antibody responses against subtype BC HIV-1 viruses circulating in China.

Zhang M, Zhang L, Zhang C, Hong K, Shao Y, Huang Z, Wang S, Lu S.

Hum Vaccin Immunother. 2012 Nov 1;8(11):1630-7. doi: 10.4161/hv.21648. Epub 2012 Oct 30.

12.

Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.

Hu JK, Crampton JC, Cupo A, Ketas T, van Gils MJ, Sliepen K, de Taeye SW, Sok D, Ozorowski G, Deresa I, Stanfield R, Ward AB, Burton DR, Klasse PJ, Sanders RW, Moore JP, Crotty S.

J Virol. 2015 Oct;89(20):10383-98. doi: 10.1128/JVI.01653-15. Epub 2015 Aug 5.

13.

Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers.

Ringe RP, Ozorowski G, Rantalainen K, Struwe WB, Matthews K, Torres JL, Yasmeen A, Cottrell CA, Ketas TJ, LaBranche CC, Montefiori DC, Cupo A, Crispin M, Wilson IA, Ward AB, Sanders RW, Klasse PJ, Moore JP.

J Virol. 2017 Jul 12;91(15). pii: e00677-17. doi: 10.1128/JVI.00677-17. Print 2017 Aug 1.

14.

Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.

McGuire AT, Glenn JA, Lippy A, Stamatatos L.

J Virol. 2014 Mar;88(5):2645-57. doi: 10.1128/JVI.03228-13. Epub 2013 Dec 18. Erratum in: J Virol. 2015 May;89(9):5194.

15.

Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds.

Madani N, Princiotto AM, Easterhoff D, Bradley T, Luo K, Williams WB, Liao HX, Moody MA, Phad GE, Vázquez Bernat N, Melillo B, Santra S, Smith AB 3rd, Karlsson Hedestam GB, Haynes B, Sodroski J.

J Virol. 2016 Apr 29;90(10):5031-46. doi: 10.1128/JVI.03211-15. Print 2016 May 15.

16.

Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially.

Pissani F, Malherbe DC, Robins H, DeFilippis VR, Park B, Sellhorn G, Stamatatos L, Overbaugh J, Haigwood NL.

Vaccine. 2012 Aug 10;30(37):5519-26. doi: 10.1016/j.vaccine.2012.06.042. Epub 2012 Jun 27.

17.

HIV-1 envelope glycoprotein trimer immunogenicity elicited in the presence of human CD4 alters the neutralization profile.

Forsell MN, McKee K, Feng Y, Mascola JR, Wyatt RT.

AIDS Res Hum Retroviruses. 2014 Nov;30(11):1089-98. doi: 10.1089/AID.2014.0104.

18.

Immunogenic Display of Purified Chemically Cross-Linked HIV-1 Spikes.

Leaman DP, Lee JH, Ward AB, Zwick MB.

J Virol. 2015 Jul;89(13):6725-45. doi: 10.1128/JVI.03738-14. Epub 2015 Apr 15.

19.

Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs.

Nkolola JP, Peng H, Settembre EC, Freeman M, Grandpre LE, Devoy C, Lynch DM, La Porte A, Simmons NL, Bradley R, Montefiori DC, Seaman MS, Chen B, Barouch DH.

J Virol. 2010 Apr;84(7):3270-9. doi: 10.1128/JVI.02252-09. Epub 2010 Jan 6.

20.

Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies.

McGuire AT, Hoot S, Dreyer AM, Lippy A, Stuart A, Cohen KW, Jardine J, Menis S, Scheid JF, West AP, Schief WR, Stamatatos L.

J Exp Med. 2013 Apr 8;210(4):655-63. doi: 10.1084/jem.20122824. Epub 2013 Mar 25.

Supplemental Content

Support Center